Download PDF
Thromb Haemost 1975; 33(01): 081-086
DOI: 10.1055/s-0038-1647815
Meeting of the International Committee on Thrombosis and Haemostasis — Symposium on Heparin, Basel, Switzerland, September, 1974
Schattauer GmbH

Small Doses of Heparin and a New Concept of Hypercoagulability[*]

Stanford Wessler
1   Department of Medicine, The Jewish Hospital of St. Louis and the Washington University School of Medicine, St. Louis, Mo. 63110
› Author Affiliations
Further Information

Publication History

Publication Date:
02 July 2018 (online)

    Permissions and Reprints

 

* Presented at the Symposium on Heparin, Basel, Switzerland, September, 1974.


 

  • References

  • 1 Abildgaard U. Highly purified antithrombin III with heparin cofactor activity prepared by disc electrophoresis. Scandinavian Journal of Clinical and Laboratory Investigation 1968; 21: 89.
    CrossrefPubMedGoogle Scholar
  • 2 Barton P. G, Jackson C. M, Hanahan D. J. Relationships between Factor V and activated Factor X in the generation of prothrombinase. Nature 1967; 214: 923.
    CrossrefPubMedGoogle Scholar
  • 3 Barton P. G, Yin E. T, Wessler S. Reactions of activated Factor X: phosphatide mixtures in vitro and in vivo. Journal of Lipid Research 1970; 11: 87.
    PubMedGoogle Scholar
  • 4 Bauer B. Proceedings of the First International Conference on Thrombosis and Embolism. B. Schwabe Basel 1954: 721.
    Google Scholar
  • 5 Best C. H. The known and the unknown. In: Blood Clotting and Allied Problems. Transactions of the First Conference (J. E. Flynn Ed.). Josiah Macy, Jr. Foundation; New York: 1948: 26.
    Google Scholar
  • 6 Biggs R, Denson K. W. E, Akman N, Borrett R, Hadden M. Antithrombin III, antifactor Xa and heparin. British Journal of Haematology 1970; 19: 283.
    CrossrefPubMedGoogle Scholar
  • 7 Brinkhous K, Smith H. P, Warner E. D, Seegers W. H. The inhibition of blood clotting: an unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin into thrombin. American Journal of Physiology 1939; 125: 683.
    PubMedGoogle Scholar
  • 8 Contejean C. Recherches sur les injections intraveineuses de peptone et leur influence sur la coagulabilité du sang chez le chien. Archives de Physiologie normale et pathologique 1895; 7: 45.
    PubMedGoogle Scholar
  • 9 Damus S, Hecks M, Rosenberg R. D. Anticoagulant actions of heparin. Nature 1973; 246: 355.
    CrossrefPubMedGoogle Scholar
  • 10 DeTakats G. Anticoagulants in surgery. Journal of the American Medical Association 1950; 142: 527.
    CrossrefPubMedGoogle Scholar
  • 11 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thrombosis et Diathesis Haemorrhagica 1965; 13: 516.
    PubMedGoogle Scholar
  • 12 Hanahan D. J, Papahadjopoulos D. In: Genetics and the Interaction of Blood Clotting Factors. (F. Koller Ed.). Thrombosis et Diathesis Haemorrhagica, Suppl. 17, F. K. Schattauer Verlag; Stuttgart: 1964: 71.
    Google Scholar
  • 13 Highsmith R. F, Rosenberg R. D. The inhibition of human plasmin by human antithrombin-heparin cofactor. Journal of Biological Chemistry 1974; 249: 4335.
    PubMedGoogle Scholar
  • 14 Howell W. H. The coagulation of blood. Harvey Lectures 1916; 2: 272.
    PubMedGoogle Scholar
  • 15 von Kaulla E, von Kaulla K. M. Oral contraceptives and low antithrombin III activity. Lancet 1970 1970; 36 1
    PubMedGoogle Scholar
  • 16 Lenggenhager K. Genese und Prophylaxis der postoperativen Fernthrombose Helvetica Chirurgica Acta. 24: 316 1957;
    PubMedGoogle Scholar
  • 17 Lyttleton J. W. Antithrombin activity of heparin. Biochemical Journal 1954; 58: 15.
    CrossrefPubMedGoogle Scholar
  • 18 Marciniak E. Factor Xa inactivation by antithrombin III. Evidence for biological stabilization of factor Xa by factor V-phospholipid complex. British Journal of Haematology 1973; 24: 391.
    PubMedGoogle Scholar
  • 19 Marciniak E, Tsukamura S. Two progressive inhibitors of factor Xa in human blood. British Journal of Haematology 1972; 22: 341.
    CrossrefPubMedGoogle Scholar
  • 20 Monkhouse F. C, France E. S, Seegers W. H. Studies on antithrombin and heparin cofactor activities of fraction adsorbed from plasma by aluminum hydroxide. Circulation Research 1955; 3: 397.
    CrossrefPubMedGoogle Scholar
  • 21 Morowitz R. The chemistry of blood coagulation. Springfield Charles C. Thomas.
    PubMedGoogle Scholar
  • 22 Peterson R, Krull P. E, Finley P, Ettinger M. C. 1970; Changes in antithrombin III and plasminogen induced by oral contraceptives. American Journal of Clinical Pathology 1968; 53: 468.
    PubMedGoogle Scholar
  • 23 Rosenberg R. D. Heparin action. Circulation 1974; 49: 603.
    CrossrefPubMedGoogle Scholar
  • 24 Rosenberg R. D, Damus P. S. The purification and mechanism of action of human antithrombin-heparin cofactor. Journal of Biological Chemistry 1973; 248: 6490.
    PubMedGoogle Scholar
  • 25 Seegers W. H. Antithrombin – a proteinase inhibitor. Annals of the New York Academy of Sciences 1968; 146: 593.
    CrossrefPubMedGoogle Scholar
  • 26 Seegers W. H, Marciniak E. Inhibition of autoprothrombin C activity with plasma. Nature 1962; 193: 1188.
    PubMedGoogle Scholar
  • 27 Seegers W. H, Cole E. R, Harmison C. R, Monkhouse F. C. Neutralization of autoprothrombin C activity with antithrombin. Canadian Journal of Biochemistry 1964; 42: 359.
    CrossrefPubMedGoogle Scholar
  • 28 Sharnoff J. G. Results in the prophylaxis of postoperative thrombo-embolism. Surgery. Gynecology and Obstetrics 1966; 123: 303.
    PubMedGoogle Scholar
  • 29 Waugh D. F, Fitzgerald M. A. Quantitative aspects of antithrombin and heparin in plasma. American Journal of Physiology 1956; 184: 627.
    PubMedGoogle Scholar
  • 30 Wessler S, Yin E. T. The theory and practice of mini-dose heparin: a status report. Circulation 1973; 47: 671.
    CrossrefPubMedGoogle Scholar
  • 31 Wessler S, Yin E. T. The role of animal models in thrombosis: a point of departure. In: Thrombosis: Pathogenesis and Clinical Trials (Deutsch, E., Brinkhous, K. M., Lechner, K. and Hinnom, S. Eds.). F. K. Schattauer Verlag; Stuttgart-New York: Thrombosis et Diathesis Haemorrhagica, Suppl. 59 83-90 1974.
    Google Scholar
  • 32 Wiseman R. Several chirurgical treatises. Ed. 2 Norton and Macock; London: 1676: 64.
    Google Scholar
  • 33 Yin E. T, Wessler S. Investigation of the apparent thrombogenicity of thrombin. Thrombosis et Diathesis Haemorrhagica 1968; 20: 465.
    PubMedGoogle Scholar
  • 34 Yin E. T, Wessler S. Evidence for a naturally occuring plasma inhibitor of activated factor X: its isolation and partial purification. Thrombosis et Diathesis Haemorrhagica 1969; 21: 398.
    PubMedGoogle Scholar
  • 35 Yin E. T, Wessler S. Heparin-accelerated inhibition of activated factor X by its natural inhibitor. Biochimica et Biophysica Acta 1970; 201: 387.
    CrossrefPubMedGoogle Scholar
  • 36 Yin E. T, Wessler S, Stoll P. Biological properties of the naturally occuring plasma inhibitor to activated factor X. Journal of Biological Chemistry 1971; 246: 3703.
    PubMedGoogle Scholar
  • 37 Yin E. T, Wessler S, Stoll P. Identity of plasma activated factor X inhibitor with antithrombin III and heparin cofactor. Journal of Biological Chemistry 1971; a 246: 3712.
    PubMedGoogle Scholar
  • 38 Yin E. T, Wessler S, Stoll P. Rabbit plasma inhibitor of the activated species of blood coagulation Factor X: purification and some properties. Journal of Biological Chemistry 3694. b 1971; 246
    PubMedGoogle Scholar
  • 39 Yin E. T, Wessler S, Butler J. V. Plasma heparin: a unique practical, submicrogram-sensitive assay. Journal of Laboratory and Clinical Medicine 1973; 81: 289.
    PubMedGoogle Scholar